Usage of Rotarix® in neonatal units across the United Kingdom

Hussain Alsaffar; Katherine Woodger; Ignatius Losa

doi:10.4172/2157-7560.1000240

Usage of Rotarix® in neonatal units across the United Kingdom

Hussain Alsaffar, Katherine Woodger, Ignatius Losa^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Following advice and recommendations by the Joint Committee on Vaccination and Immunisation (JCVI), and in line with standing commitments on patient rights under the NHS constitution on implementing such recommendations, a series of changes to England's national immunisation programme took place from July 2013 including the introduction of Rotavirus vaccine (Rotarix® by GlaxoSmithKline Biologicals s.a.) into the routine childhood UK schedule for babies from 2 months of age [1].

Original language	English
Article number	1000240
Journal	Journal of Vaccines and Vaccination
Volume	5
Issue number	4
DOIs	https://doi.org/10.4172/2157-7560.1000240
Publication status	Published - 2014
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Drug Discovery
Virology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4172/2157-7560.1000240

Cite this

@article{81ca8585106044fe9acbf1b61cee3773,

title = "Usage of Rotarix{\textregistered} in neonatal units across the United Kingdom",

abstract = "Following advice and recommendations by the Joint Committee on Vaccination and Immunisation (JCVI), and in line with standing commitments on patient rights under the NHS constitution on implementing such recommendations, a series of changes to England's national immunisation programme took place from July 2013 including the introduction of Rotavirus vaccine (Rotarix{\textregistered} by GlaxoSmithKline Biologicals s.a.) into the routine childhood UK schedule for babies from 2 months of age [1].",

author = "Hussain Alsaffar and Katherine Woodger and Ignatius Losa",

year = "2014",

doi = "10.4172/2157-7560.1000240",

language = "English",

volume = "5",

journal = "Journal of Vaccines and Vaccination",

issn = "2157-7560",

publisher = "OMICS Publishing Group",

number = "4",

}

TY - JOUR

T1 - Usage of Rotarix® in neonatal units across the United Kingdom

AU - Alsaffar, Hussain

AU - Woodger, Katherine

AU - Losa, Ignatius

PY - 2014

Y1 - 2014

N2 - Following advice and recommendations by the Joint Committee on Vaccination and Immunisation (JCVI), and in line with standing commitments on patient rights under the NHS constitution on implementing such recommendations, a series of changes to England's national immunisation programme took place from July 2013 including the introduction of Rotavirus vaccine (Rotarix® by GlaxoSmithKline Biologicals s.a.) into the routine childhood UK schedule for babies from 2 months of age [1].

AB - Following advice and recommendations by the Joint Committee on Vaccination and Immunisation (JCVI), and in line with standing commitments on patient rights under the NHS constitution on implementing such recommendations, a series of changes to England's national immunisation programme took place from July 2013 including the introduction of Rotavirus vaccine (Rotarix® by GlaxoSmithKline Biologicals s.a.) into the routine childhood UK schedule for babies from 2 months of age [1].

UR - http://www.scopus.com/inward/record.url?scp=84907369576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907369576&partnerID=8YFLogxK

U2 - 10.4172/2157-7560.1000240

DO - 10.4172/2157-7560.1000240

M3 - Article

AN - SCOPUS:84907369576

SN - 2157-7560

VL - 5

JO - Journal of Vaccines and Vaccination

JF - Journal of Vaccines and Vaccination

IS - 4

M1 - 1000240

ER -

Usage of Rotarix® in neonatal units across the United Kingdom

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this